HEALTH SCIENCES ACQUISITIONS CORP 2 HSAQ 深 滬
等待開盤 11-11 09:30:00 美东时间
13.31
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 13.31
- 總市值 14.92万
- 52周最高 13.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 9.41
- 委 比 0.00%
- 總股本 1.12万
- 歷史最高 14.66
- 量 比 0
- 振 幅 0.00%
- 歷史最低 9.41
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
Attovia Therapeutics announced positive 12-week results from its Phase 1b study of ATTO-1310, a next-generation anti-IL-31 therapy, in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD). The study demonstrated rapid, deep, and durable itch relief, sustained skin lesion improvements, and approximately 95% suppression of IL-31 through Week 12, supporting potential quarterly dosing. The company plans to initiate Phase 2 trials ...
11-05 21:05
Endovia Health Sciences Files Prospectus Related To Potential Resale Of Up To 1,013,041 Shares Of Common Stock By Selling Stockholder
Endovia Health Sciences Files Prospectus Related To Potential Resale Of Up To 1,013,041 Shares Of Common Stock By Selling Stockholder
10-28 05:33
Endovia expands equity line, boosting financing capacity
Endovia Health Sciences Inc ( ($EDVA) ) has shared an update. On October 22, 20...
10-28 04:28
Hawkins, Inc. Declares Quarterly Cash Dividend of $0.20 Per Share
Hawkins, Inc. (Nasdaq: HWKN) announced a quarterly cash dividend of $0.20 per share, payable on November 25, 2026, to shareholders of record as of November 11, 2026. The company, founded in 1938, has consistently paid dividends since 1985. Based in Roseville, Minnesota, Hawkins operates in water treatment, food and health sciences, and industrial solutions, with 69 facilities across 28 states. It generated approximately $1.1 billion in revenue in...
10-26 20:05
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio has submitted Marketing Authorization Applications (MAAs) for tinlarebant in Singapore, the UK, and Switzerland to treat Stargardt disease type 1 (STGD1). Tinlarebant, an investigational oral therapy, aims to slow retinal lesion growth in STGD1, a rare, inherited disease with no approved treatments in these regions. The MAA submissions via the Access Consortium framework support Belite’s global goal to bring tinlarebant to STGD1 patien...
10-14 20:00
Endovia Health Raises Capital Through Recent Equity Issuance
The latest announcement is out from Endovia Health Sciences Inc ( ($EDVA) ). On...
10-07 04:29
Endovia Gains MUMS Status for CannEpil Canine Therapy
Endovia Health Sciences Inc ( ($EDVA) ) has provided an announcement. On Octobe...
10-06 04:32
Hawkins, Inc. to Release Second Quarter Fiscal 2027 Financial Results on October 26, 2026
Hawkins, Inc. announced it will release its second quarter fiscal 2027 financial results ended September 27, 2026, after market close on October 26, 2026, at approximately 4:10 p.m. Eastern Time. Founded in 1938, Hawkins is a leading water treatment and specialty ingredients company with 69 facilities in 28 states, serving customers in Water Treatment, Food & Health Sciences, and Industrial Solutions. The company generated approximately $1.1 bill...
10-05 13:00
Endovia Secures New Funding to Advance CannEpil Program
The latest announcement is out from Endovia Health Sciences Inc ( ($EDVA) ). On...
09-25 04:53
Endovia secures $500,000 convertible financing for CannEpil
Endovia Health Sciences Inc ( ($EDVA) ) just unveiled an announcement. Endovia ...
09-23 04:28
